基于线粒体靶点的心血管疾病干预研究进展  

Therapeutic studies progress on cardiovascular diseases by targeting mitochondrial damage

作　　者：王莹雪 孙树秋[1] Wang Yingxue;Sun Shuqiu(Institute of Keshan Disease,Center for Endemic Disease Control,Chinese Center for Disease Control and Prevention,Harbin Medical University,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学中国疾病预防控制中心地方病控制中心克山病防治研究所,150081

出　　处：《中华地方病学杂志》2020年第12期933-936,共4页Chinese Journal of Endemiology

基　　金：国家自然科学基金(81573099)。

摘　　要：心脏活动高度依赖线粒体腺嘌呤核苷三磷酸(ATP)能量供应。以线粒体为靶点的心血管疾病治疗通过修复受损线粒体DNA、降低线粒体活性氧(ROS)生产、加速损伤线粒体的降解及再循环利用等途径开发新药。近年来,线粒体替代疗法另辟蹊径,已发展到临床试用阶段。本文对以线粒体为靶点的心血管疾病治疗药物和线粒体替代疗法两方面的研究进展进行综述,旨在为我国地方病心血管健康问题防治提供新视角。Heart activity is highly dependent on adenosine triphosphate(ATP)produced via mitochondrial oxidative phosphorylation.Traditional therapeutics has developed drugs by repairing damaged mitochondrial DNA,reducing mitochondrial reactive oxygen species(ROS)production,and accelerating the degradation of damaged mitochondria and recycle.In recent years,however,mitochondrial replacement therapy has taken a different strategy,and has entered the clinical trial stage.This review will summarize the research progress of cardiovascular drugs targeting mitochondria and mitochondrial replacement therapy to provide a new perspective for addressing some relevant endemic diseases in China.

关 键 词：心血管疾病 线粒体 靶向干预 置换疗法 

分 类 号：R54[医药卫生—心血管疾病]